(Total Views: 683)
Posted On: 02/23/2021 4:40:30 AM
Post# of 154011
Look at all the SOD1 involved...the questions now are:
- why you're finally acknowledging it, and
- how long it will take you to read enough to understand the difference between inflammation causing disease and inflammation as a result of disease
?
Maybe LLMab can slow progression in specific cases. Most likely any effects will be minimal. More likely not, as all the other failed immune modulation / suppression studies have shown. It's not a cure; it's not gene therapy, it won't restore enzymatic activity.
The list of indications that have valid pathology overlap with LLMab's MOA is plenty long, if ALS is on that list, it's at the very bottom.
- why you're finally acknowledging it, and
- how long it will take you to read enough to understand the difference between inflammation causing disease and inflammation as a result of disease
?
Maybe LLMab can slow progression in specific cases. Most likely any effects will be minimal. More likely not, as all the other failed immune modulation / suppression studies have shown. It's not a cure; it's not gene therapy, it won't restore enzymatic activity.
The list of indications that have valid pathology overlap with LLMab's MOA is plenty long, if ALS is on that list, it's at the very bottom.
(2)
(1)
